Table 4.
Median survival time and percentage survival at 1, 2, 3 and 5 years in patients with hepatocellular carcinoma by Barcelona Clinic Liver Cancer (BCLC) stage at the index visit
| Characteristics | BCLC stage | Total (n = 254) | P-valuea | ||||
|---|---|---|---|---|---|---|---|
| 0 (n = 8) | A (n = 76) | B (n = 105) | C (n = 48) | D (n = 17) | |||
| Median survival, months | 23.5 | 19.5 | 18.0 | 50 | 3.0 | 16.0 | <0.0001 |
| Overall survival, % | |||||||
| 1-year (n = 247)b | 100% | 83.3% | 67.6% | 29.2% | 29.4% | 63.2% | <0.0001 |
| 2-year (n = 223)b | 57.1% | 57.6% | 40.9% | 14.9% | 17.6% | 38.6% | <0.0001 |
| 3-year (n = 213)b | 57.1% | 42.6% | 23.3% | 8.9% | 11.8% | 25.4% | 0.0004 |
| 5-year (n = 199)b | 33.3% | 25.5% | 9.4% | 0% | 6.3% | 11.6% | 0.001 |
a
P-values were calculated using Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.
b
For each time period, the number used to calculate percentage survival includes patients who died during follow-up and those remaining alive and not lost to follow-up at the end of the designated time period.